Lifileucel Shows Long-Term Efficacy in Melanoma
Source: Targeted Oncology, March 2024
In patients with advanced melanoma, lifileucel showed durable efficacy and a 4-year overall survival rate of 21.9%, according to long-term findings from the phase 2 C-144-01 trial.
A 4-year follow-up study evaluating the tumor infiltrating lymphocyte cell therapy lifileucel (LN-144) in patients with advanced melanoma showed durable efficacy and a 4-year overall survival (OS) rate of 21.9%, according to long-term findings from the phase 2 C-144-01 trial (NCT02360579) presented at the
European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023.
These findings led to an FDA approval for the cellular therapy in this patient population.